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Recent case-referent studies in the Nijmegen breast- 
screening programme have shown a reduction in breast- 
cancer mortality of approximately 50% due to screening of 
women aged 65 years and older. In this type of study, 
however, the results may be biased because of self-selection. 
The purpose of our present study was to compare the 
breast-cancer mortality rate in a population invited for 
screening with that of a reference population from an area 
without a screening programme. In 1977-1978, 6773 women 
aged 68-83 years were enrolled in the mammographic screen­
ing programme in Nijmegen, The Netherlands. The women 
were followed up until 31 December, 1990. The reference 
population consisted of women from the same birth cohort 
from Arnhem, a neighbouring city without mass screening, 
for whom the entry date was I January, 1978. The ratios of 
the Nijmegen and Arnhem breast-cancer mortality rates 
with 95% confidence intervals (Cl) were calculated. In the 
study period, 173 patients were diagnosed with primary 
breast cancer in Nijmegen vs. 183 in Arnhem; 40 Nijmegen 
patients had died of breast cancer vs. 5 1 Arnhem patients. 
The cumulative mortality-rate ratio was 0.80 (95% Cl =  0.53- 
1.22). In the periods 1978-1981, 1982-1985 and 1986-1990, 
the mortality rate ratios were 1.44 (95% Cl = 0.67-3.10), 0.81 
(95% Cl = 0.37-1.79) and 0.53 (95% Cl = 0.27-1.04), respec­
tively. After adjustment for the difference in incidence rate 
that existed between the Nijmegen and Arnhem populations, 
mammographic screening of women older than 65 can be 
expected to yield a 40% reduction in breast-cancer mortality 
after 10 years. Int.J. Cancer, 70:164-168, /997*
© J997 Wiley-Liss, Inc,
Unlike most malignancies, the course of breast cancer can be 
altered by early detection and treatment. In women over the age of
50 years» trials have shown a reduction of breast-cancer mortality 
of some 25 to 30% in populations that were offered screening vs. 
unscreened populations (Fletcher e ta l , 1993; Ny strom et at., 1993; 
De Koning et al, 1995; Kerlikowske et al., 1995). The screening 
intervals used in these studies ranged from 12 to 33 months and the 
screening test consisted of 1- or 2-view mammography, sometimes 
in combination with physical examination.
More recently, a reduction in mortality has been demonstrated in 
women up to the age of 75 years (Van Dijck et a l , 1994, 1996; 
Chen et al., 1995). The results of the Swedish 2-county study, 
which was a randomized trial, showed a decrease in breast-cancer 
mortality due to the screening of women aged 65 to 74 years at 
entry (Chen et al, 1995). After 14 years of follow-up, a statistically 
significant 32% reduction in the risk of death from breast cancer 
was observed in the population invited for screening. In Nijmegen,
2 case-referent studies included women aged 65 years and older at 
the index invitation {i.e., the most recent invitation to screening just 
prior to the diagnosis of breast cancer in the case). The estimated 
reductions in breast-cancer mortality in women screened at the 
index invitation relative to those unscreened at that time were 42% 
and 44% after 13 and 18 years of follow-up respectively (Van Dijck 
et al, 1994, 1996). There has been debate, however, on the validity 
of case-referent studies as a method of evaluating screening
efficacy, since the results may be biased due to self-selection for 
screening (Morrison, 1993; Moss et al, 1992). The present study 
used an external reference population to evaluate whether includ­
ing elderly women in a screening programme affects breast-cancer 
mortality.
SUBJECTS AND METHODS
In 1975, a breast-cancer screening programme was started in the 
city of Nijmegen, The Netherlands (Otten et al, 1996). Initially, 
women born between 1910 and 1939 (aged 35-66 years) were 
invited for one-view mammography. Since the second round of 
screening, 1977-1978, women born before 1910, aged 67 years and 
older at their first invitation, have also been invited biennially to 
participate in the screening. The present study included all Nijme­
gen women born between 1895 and 1909 who had been invited to 
screening before the end of 1990. In this way, 6773 women entered 
the screening programme in round 2, while 488 women, who had 
come to live in Nijmegen after round 2, joined the programme
between 1979 and 1990.
Information about invitation and participation of the invited 
women was stored in a computer file. With the aid of the local 
authorities, follow-up could be recorded. All patients diagnosed 
with breast cancer (screen-detected and clinically diagnosed) at 
either of the 2 Nijmegen hospitals were registered at the Depart­
ment of Radiology of the University Hospital. Clinical information 
about deceased patients was obtained from their medical files and 
reviewed by a panel of physicians who were unaware of the 
screening history of the patients. The cause of death was ascer­
tained based on the clinical course of the disease and information 
about any serious co-morbidity, Breast cancer was defined as the 
cause of death if the disease had progressed to distant sites and if 
this progression could not be ruled out as the cause of death of the 
patient.
The reference population consisted of inhabitants of Arnhem, a 
city located 20 kilometers north of Nijmegen, where mass screen­
ing was started in 1989 for women aged 50 to 69 years as part of the 
national programme in The Netherlands. The Arnhem patients were 
registered by the “Carcinoma Work Group” , which operated until 
1991. With the aid of the local authorities, patients who had died or 
moved away from Arnhem could be identified. The cause of death 
of deceased patients was established in the same manner as that 
described above and by the same physicians as in Nijmegen.
For Arnhem, person-years of observation had to be calculated 
from the official census statistics published annually by the Dutch
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Central Bureau of Statistics. These statistics keep track of the 
number of inhabitants of each sex, by year of birth, on 1 January of 
each calendar year. Although data for Nijmegen were available on 
an individual basis, woman-years were also calculated on the basis 
of the census statistics for the sake of comparability of the 
information. For each calendar year up to and including 1990, the 
mid-year population size was calculated as the number of woman- 
years of observation in that year.
Breast-cancer mortality rates in Nijmegen were based on data 
from patients in whom breast cancer had been diagnosed after the 
invitation to the first round of screening in 1977-1978. For 1977 
and 1978, a population-time correction was made according to the 
exact entry dates. The mortality rates in Arnhem were based on data 
from patients diagnosed from 1 January, 1978, onwards, since this 
was close to the median date of the first invitation for the Nijmegen 
population (55% had been invited by then). Patients diagnosed with 
breast cancer before this date were excluded from the analysis. The 
ratio of the cumulative breast-cancer mortality rates (Le>, number 
of breast-cancer deaths in the entire study period divided by the 
total number of woman-years) was calculated, as well as the ratios 
of breast-cancer mortality rate over 3 periods. Confidence intervals 
(Cl) were calculated using the method based on the standard 
deviation of the log-transformed point estimates (Rothman, 1986«)-
Participation
RESULTS
In Nijmegen, 7261 women born between 1895 and 1909 had 
been invited for screening in the period 1977 to 1990, A total of 
46% had participated in the screening programme at least once, and 
half of these women had taken part more than once. A marked 
decrease in the participation rate was observed as the round number 
and age increased, illustrated in Figure 1 for rounds 2, 5 and 8, In 
rounds 2 to 8, overall participation rates were 43%, 29%, 22%, 
15%, 12%, 10% and 4% respectively.
In Nijmegen, 173 patients were diagnosed as having breast 
cancer, vs. 183 in Arnhem. Breast cancer had been diagnosed in 
Nijmegen: ( I) after a positive screening examination in 57 patients, 
(2) after a negative screening mammogram (interval cancer) in 21 
patients, (3) before the first invitation in 4 patients who had moved 
to Nijmegen after 1977, and (4) after a refused invitation in 91 
non-participant cases.
Table I shows the number of patients who had died from breast 
cancer, also the woman-years of observation for each calendar year. 
Two deaths occurred in patients diagnosed before their first 
invitation who had moved to Nijmegen after 1978. For both 
populations, the breast-cancer mortality rates (5-year moving 
average) are displayed in Figure 2. Up to 6 years after the start of 
screening, the breast-cancer mortality rate in Nijmegen was higher 
than that in Arnhem. In the subsequent years, the rate in Nijmegen 
stabilized, but an increase was observed in the late eighties. In 
Arnhem, the rate reached its maximum after 10 years and 
continued to decrease afterwards.
Over the entire study period, breast-cancer mortality in Nijme­
gen was lower than in Arnhem: cumulative mortality-rate ratio =
0.80 (95% Cl, 0.53-1.22). Table II shows the ratio of the 
breast-cancer mortality rates with 95% Cl over several periods. In 
the first period of 4 years, the mortality-rate ratio was 1.44, in the 
.second period of 4 years it was 0.81, whereas in the relevant 
observation period, 9 to 13 years after the start of screening, it was
0.53 (95% Cl, 0.27-1.04).
DISCUSSION
According to the results, the effect of screening manifests itself 
approximately 7 years after the start of the programme and reaches 
its maximum after about 10 years. This is what one would expect if 
analyses include only patients in whom breast cancer was diag­
nosed after the start of the screening programme. The proportion of
F i g u r e  1 -  Participation rate according to age at invitation for 
screening rounds 2, 5 and 8.
TABLE I -  NUMBER OF BREAST-CANCER DEATHS AND WOMAN-YEARS




BrT a t h s ' Cer Woman-ycats B ^ d e a f f  C Cr Wo m an - y e a r s
1978 1 6823-1 I 6502
1979 1 6248 3 6222
1980 8 4 5947 I 5961
1981 64 5620 6 5725
1982 3 5284 I 5455
1983 4 4967 3 5155
1984 2 4669 6 4836
1985 2 4378 4 4494
1986 1 3988 9 4174
1987 3 3567 6 3863
1988 55 3224 6 3526
1989 36 2944 5 3156
1990 I 2656 0 2765
1977-1990 40 60313 51 61832
*Only if diagnosed after first invitation in round 2.-20 nly if 
diagnosed after 31 December 1977.—3Including 1977,-4lneluding 1 
death in patient diagnosed before enrollment, but after round 2 -  
5Including 1 death with breast-cancer métastasés.-including 3 deaths 
with breast-cancer métastasés-Cumulative mortality-rate ratio 0.80 
(95% Cl, 0.53-1.22).
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F i g u r e  2 -  Breast-cancer mortality rates (5-year moving average) in 
Nijmegen, if diagnosed after first invitation 1977-78, and in Arnhem, if 
diagnosed from 1978 onwards.
TABLE II -  BREAST-CANCER DEATHS AND WOMAN-YEARS IN NIJMEGEN AND 




rate ratio (95% Cl)Deaths' Woman-years Deaths2
Woman-
years
1978-1990 163 60325 51 61845 0.80 (0.53-1.22)
1978-1981 16 24641 il 24415 1.44 (0.67-3.10)
1982-1985 11 19301 14 19943 0.81 (0.37-1.79)
1986-1990 I33 16383 26 17487 0.53(0.27-1.04)
'If diagnosed after first invrtation.~2If diagnosed from 1-1-1978 
onwards.-3Including 4 deaths with breast-cancer métastasés.
women who participated in the programme decreased gradually, so 
the effect of screening on breast-cancer mortality can also be 
expected to decrease gradually. It is likely that the effect will have 
diminished 15 to 20 years after the start of screening.
Could the observed mortality reduction be due to screening 46% 
of the population only, while half of these women had been 
screened at least twice? In an earlier study, the incidence of breast 
cancer in Nijmegen and Arnhem was compared in women aged 65 
years and older. In the period 1979 to 1988, the incidence rate of 
breast cancer in Nijmegen (adjusted for age in 5-yeai* categories: 
65-69, 70-74, 75-79, 80-84 and 85+) equalled that in Arnhem 
(RR, 0.97; 95% Cl, 0.83-1.14), whereas in the Nijmegen non­
Calendar year
F i g u r e  3  -  Breast-cancer incidence rates (5-year moving average) 
in the Nijmegen and Arnhem populations born between 1895 and 1909.
participants, the incidence was much lower than that in Arnhem 
(RR, 0.72; 95% Cl, 0.56-0.93). Therefore the incidence of breast 
cancer in the participants must have been much higher than in the 
non-participants (Van Dijck et al, 1996). We concluded that the 
women who do participate in the screening are at increased risk for 
breast cancer. As a consequence, actual participation may have a 
relatively large effect on breast-cancer mortality in the population.
An important question is whether the populations of Nijmegen 
and Arnhem would have had the same breast-cancer mortality in 
the absence of screening. This cannot be derived directly, but it can 
be analyzed using an indirect approach by comparing the incidence 
of breast cancer. For the period 1975 to 1990, Figure 3 shows the 
incidence rates of primary breast cancer (5-year moving averages) 
in Nijmegen and Arnhem in women born between 1895 and 1909. 
In almost every calendar year, the incidence in Nijmegen was lower 
than in Arnhem. It was only higher in Nijmegen in 1977 to 1981, 
when rounds 1 and 2 took place for this birth cohort. In the early 
eighties, the incidence rate in Nijmegen declined, possibly due to 
the start of screening in the late seventies. Table III shows the 
number of diagnosed patients and the woman-years of observation, 
as well as the incidence-rate ratio for 4 periods. The incidence-rate 
ratio was 0.90 (95% Cl, 0.75-1.07), adjusted for these 4 periods 
(directly weighted pooled estimate (Rothman, 1986b, 1996c). 
Correction of the mortality-rate ratio over the relevant observation 
period 1986 to 1990 gave an estimate of 0.59 (95% Cl, 0.30-1.16).
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TABLE III -  NUMBER OF DIAGNOSED BREAST-CANCER PATIENTS AND 
WOMAN-YEARS IN NIJMEGEN AND ARNHEM IN 4 SPECIFIED PERIODS AND












1975--1990 226 81220 257 82891 0 .90 ' (0 .7 5 -1 .0 7 )
1975--1976 38 14378 50 14317 0.76  (0 .5 0 -1 .1 5 )
1977--1980 84 25545 71 25425 1.18 (0 .8 6 -1 .6 2 )
1981--1985 61 24918 83 25665 0 .7 6 (0 .5 4 -1 .0 5 )
1986--1990 43 16379 53 17484 0.87 (0 .5 8 -1 .2 9 )
'Directly weighted pooled estimate (Rothman, 1986b,c).
Besides incidence, prognosis is also a modifier of breast-cancer 
mortality. Differences in prognosis could result from differences in 
treatment between Nijmegen and Arnhem. In Nijmegen, 30% of 
the patients were diagnosed and treated at the University hospital, 
while the remainder were patients at the other Nijmegen hospital. 
At the latter, a “Diagnostic Mamma Team” has been established, 
comprising radiologists, pathologists and surgeons from the 2 
hospitals. Once a week, all the patients are discussed. The goal of 
these weekly discussions is to reduce the number of invasive 
diagnostic procedures. Although the patients from the 2 cities were 
treated according to protocols, the monitoring of diagnostic 
procedure may have influenced the decision for treatment.
A difference may have existed in the extent of misclassification 
of the cause of death. The procedures followed and the criteria used 
to ascertain the cause of death were identical for the Nijmegen and 
Arnhem patients. However, the physicians who made the classifica­
tion were not blinded for city. Although unlikely, this may have led 
to differential misclassification. It is also possible that the informa­
tion available in Nijmegen was more extensive than in Arnhem, for 
instance due to the “Diagnostic Mamma Team” . An indication that 
this may have been the case was the fact that the deaths of 4 
Nijmegen patients had been classified as “death from other cause 
with metastases of breast cancer,” whereas no Arnhem patients had 
been classified as such. This category was used only during the last
3 years. Previously, deaths had been classified as either “due to 
breast cancer” or “due to other causes” .
Several case-referent studies have been conducted in Nijmegen. 
In women aged 67 years or older at entry, breast-cancer mortality 
after 6 years of follow-up for those screened at least once was 19% 
lower (RR, 0.81; 95% Cl, 0.23-2,75) than in those who had never 
been screened (Verbeek et aL, 1985). In the study reported in J 994, 
the follow-up period was 12 years (Van Dijck et aL, 1994). In 
women aged 65 years and older who had been invited for screening 
at least twice, breast-cancer mortality in those who had participated 
in the most recent screening was 42% lower than in those who had 
rejected it (RR, 0.58; 95% Cl, 0.24-1.41). In those aged 65 to 74, 
the reduction in breast-cancer mortality was 66% (RR, 0.34; 95%
Cl, 0.12-0.97). Our most recent study on women aged 65 years and 
older after 17 years of follow-up showed that breast-cancer 
mortality was 44% lower (RR, 0.56; 95% Cl, 0.28-1.13) in women 
who had been screened regularly (i.e., after the 2 most recent 
invitations) than in women who had not been screened in the past
10 years (Van Dijck e t  ciL, 1996). In women aged 65 to 74 years the 
reduction in 3 case-referent studies, contrast was made between 
women who were screened and those who were not. The design of 
the present study was quite different, because contrast was made 
between the invited Nijmegen population, regardless of their actual 
screening history, and the uninvited Arnhem population. The most 
important reason for this design was to avoid bias due to 
self-selection. However, the price to be paid was a loss of contrast, 
because less than 50% of the invited population participated in at 
least one screening round.
The Swedish 2-county trial is the only other project with a long 
follow-up that included women aged 70 years and older. In that 
randomized study, the participation rate was 86% in women aged 
65 to 69 and 77% in women aged 70 to 74 years. Women of over 74 
years were excluded from all the analyses, because of the low 
participation rate of approximately 50%, After 14 years, the ratio of 
the cumulative risk (i.e., number of deaths to the number of women 
enrolled) in the women aged 65 to 74 years at entry was 0.68 (95% 
Cl, 0,51-0,89), which is much larger than in the Nijmegen invited 
population (cumulative rate ratio, 0.80). However, after the partici­
pation rate had been accounted for, the results compared very well.
The results of the present study, although in themselves inconclu­
sive because of the wide confidence intervals, show a reduction in 
breast cancer mortality in women who were older than 65 years at 
entry to the screening programme. After 10 years, the reduction in 
breast cancer mortality may be as large as 40%. In an analysis of 
the positive and negative effects of screening after the age of 65 
years, Boer and colleagues (1995) showed that, under optimistic 
assumptions, this balance may never become negative. Under 
pessimistic assumptions the positive effects may outweigh the 
negative effects until the age of 80 years. When the upper age limit 
of a screening programme is increased, however, the cost- 
effectiveness ratio will increase, for 2 reasons; the number of 
life-years gained will be less and the negative effects and the cost of 
screening will increase.
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